Asymmetric Catalysts for 6-Keto Morphinan Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing 6-keto morphinans to 6-α-hydroxy morphinans suffer from low yields and difficulties in purification, requiring repeated extractions and lengthy distillations, with boron-derived reducing agents often resulting in low epimeric purity and inefficient isolation processes.
Innovation Solution
The use of ruthenium, rhodium, or iridium asymmetric catalysts in conjunction with a hydrogen source to selectively convert 6-keto morphinans to 6-α-hydroxy morphinans, allowing for high epimeric ratios and simplified isolation through N-alkylation or other modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If boron-derived reducing agents are used to reduce 6-keto morphinans, then the reduction reaction can be performed, but the epimeric purity is low and the isolation process is inefficient
Solution Approach 1:
The patent changes the chemical parameters by substituting boron-derived reducing agents with transition metal catalysts (ruthenium, rhodium, or iridium complexes) and adjusting the reaction conditions (temperature, solvent, hydrogen source) to achieve both high epimeric purity (>99:1) and improved isolation efficiency through simplified workup procedures
Solution Approach 2:
The patent replaces the chemical mechanism of boron hydride reduction with a catalytic hydrogenation mechanism using transition metal complexes, which provides better stereocontrol and eliminates the need for complex extraction and distillation procedures required by the boron-based method
2Manufacturing precision
If repeated extractions and lengthy distillations are performed to isolate the product, then purification is achieved, but the process time and complexity increase
Solution Approach 1:
The patent takes out the need for repeated extraction steps by using a catalytic system that produces cleaner reactions with fewer byproducts, allowing isolation through simpler filtration and concentration procedures while maintaining high purification quality
Solution Approach 2:
The patent performs preliminary optimization of the reaction conditions and catalyst selection to ensure high selectivity and clean reaction profiles before isolation, preventing the formation of difficult-to-remove byproducts that would require lengthy distillation and repeated extraction
3Productivity
If higher temperatures are used for the reduction reaction, then the reaction rate increases, but the epimeric ratio decreases
Solution Approach 1:
The patent changes the temperature parameter to optimized ranges (typically -78°C to 0°C) that balance reaction rate and stereoselectivity, and compensates for the lower temperature by using highly active transition metal catalysts that maintain efficient catalysis under these conditions
Solution Approach 2:
The patent uses composite catalytic systems combining transition metal complexes with specific ligands (such as chiral phosphine ligands or N-heterocyclic carbenes) that enhance both the activity and stereoselectivity of the catalyst, allowing efficient reduction at lower temperatures with high epimeric ratios
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves high epimeric purity, with epimeric ratios often greater than 99:1, and simplifies the isolation of 6-α-hydroxy morphinans, improving the overall efficiency and yield of the conversion process.
Implementation Method 1
the 6-keto group has been reduced using boron reducing agents
Implementation Method 2
reacting a 6-keto morphinan (I) in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source
Data Source
AI summary
The present invention is directed to the conversion of a 6-keto morphinan to a 6-alpha-hydroxy morphinan in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source.